Retatrutide, a innovative dual-acting glucose-responsive incretin agent, represents a significant progression in peptide treatments for the management of type 2 diabetes and, increasingly, excess adiposity. Unlike many existing therapeutic interventions, retatrutide combines the actions of a GLP-1 receptor agonist and a GIP receptor activator, offe